Aggarwal @docrota et al. RCT abatacept in IIM - 52 week results. IMACS DOI, FI-2, HAQ-DI, CDASI, TIS, MRC response all numerically better, some statistically significant. There looks like a real effect across all subtypes. @RheumNow #ACR22 Abstr#2237 https://t.co/NdkH8BnSEw https://t.co/l7ufagjniX

• Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Subcutan…

Kim et al. After first episode VZV in RA or UC treated with JAKi, continued JAKi use does not increase reactivation compared to cessation. @RheumNow #ACR22 Abstr#2220 https://t.co/zx96xgkySU https://t.co/KdniDGCUgI

• Recurrence of Herpes Zoster Reactivation After Events of Herpes Zoster in Patie…

#ACR22 Abstr#1656 Promising therapy for #lupus. Cenerimod, S1P1 modulator, controls lymphocyte trafficking out of lymph nodes into blood. Phase 2 dose-ranging RCT didn't meet primary endpoint (adjusted for multiple testing) but mSLEDAI-2K reduced in 4mg dose vs PBO @RheumNow https://t.co/YnENTkqClk

Abstr #2194- What is my risk of flare after COVID vaccine? - Up to 3 wks s/p vaccination, no significant assn w/ risk for flare (aIRR 0.89 95% CI 0.8-.098) including after 1st, 2nd, and 3rd dose - No significant assn by disease, hx of COVID infxn, vaccine type @RheumNow #ACR22

Some RA patients do well. Some do badly, and get frail even before the age of 65 (6% of pts). These are the ones that get hit by infections with b/tsDMARDs: see below from MarketScan data. These are the patients we need to watch & protect! ABST2217 @NamrataRheum #ACR22 @RheumNow https://t.co/DXZjFDnCcn

Nakafero et al. Self-controlled case series analysis. No increased risk RMD flare with SARS-CoV-2 vaccination. In fact reduced risk! aIRR 0.89(0.80-0.98). No evidence in any of multiple subanalyses either @RheumNow #ACR22 Abstr#2194 https://t.co/r5pOkdjnR1 https://t.co/YpwMkJ3WVe

• Is Vaccination Against Covid-19 Associated with Autoimmune Rheumatic Disease Fl…

ACRTIC REWIND finds RA pts w/ sustained clinical remission for at least two years and successfully tapered csDMARDs to half-dose, majority of pts who discontinued csDMARDs remained flare free for 12 months. Abs 2013 #ACR22 @RheumNow https://t.co/HsQz0cJznp https://t.co/QceTXJZiFF

• Drug Free Remission in Rheumatoid Arthritis: Data from the Randomized Controlle…

🌱Plants for joints 🌱 👉16wk 👉whole food plant based diet + Phys activity + stress Mx 👉 metabolic syndrome assoc OA hip/knee 💥 substantial ⬇️ pain + stiffness 💥⬆️ physical function #ACR22 @RheumNow Abst 1644 https://t.co/u6UufpbrcC

Thanks for the love #Philly #ACR22 @RheumNow check out our coverage by logging on to https://t.co/xF1bNhZB1C! https://t.co/ncBM0icZ3c

• Home | RheumNow

Retrospective cohort study 132 immune checkpoint inhibitor arthritis pts Rx with either TNFi ± MTX or IL6Ri ± MTX have a shorter time to cancer progression but faster arthritis control than patients Rx with MTX alone. Bass A Abs#1669 https://t.co/h0Nq6yd2wf #ACR22 @RheumNow https://t.co/XfXMtdbCPB

• Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors …

Wallace @BethIWallace et al. Time dependent evaluation GCs and MACE in RA. Effect of steroids in previous 6 months on MACE risk in next 6 months. Odds MACE (vs no steroid) 1.54 (1-7 days) 1.78 (8-90 days) 2.17 (>90 days) @RheumNow #ACR22 Abstr#2219 https://t.co/w4gCgjeSNa https://t.co/TQ9pufGtBD

• Time-Dependent Evaluation of Glucocorticoid Exposure Duration and Major Adverse…

Sphygmomanometer for fibromyalgia detection in rheum OPD 🔥⬆️local pain during BP testing strongly indicates presence of FMS ✅useful, easily applicable and practical screening tool Abst#1225 #ACR22 @RheumNow

#FMF 2350 pts = 40% with arthritis - Colchicine resistance in 20% - M694V mutation carrier rate high (mutant MEFV gene) - FMF pts with arthritis have a more severe disease course - incidence of spondyloarthropathy was increased in FMF #ACR22 @RheumNow abst#1830 https://t.co/uiLhjK0UjY

Rohmer @TerrierBen et al. 196 cases of PAN from France. 28% assoc another condition - MDS and cancer mainly. Relapse in 39% - assoc age>65, GI, skin necrosis. Death assoc age>65, AKI, secondary PAN, necrotic purpura. @RheumNow #ACR22 Abstr#2232 https://t.co/fyJY9O3Gm7

• Clinical Features and Long-term Outcomes of Patients with Systemic Polyarteriti…

Tonight! Join our RA Topic Panel with panelists: Drs. Richard Conway, Aurelie Najm, David Liew, Janet Pope, Julian Segan @RichardPAConway @AurelieRheumo @drdavidliew @Janetbirdope @JulianSegan #ACR22 https://t.co/j13W4GM56w https://t.co/fgDwPVdskC

• https://bit.ly/3Ah5caJ